Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01344447




Registration number
NCT01344447
Ethics application status
Date submitted
5/04/2011
Date registered
29/04/2011
Date last updated
4/01/2019

Titles & IDs
Public title
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
Scientific title
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Contrast-Enhanced Magnetic Resonance Angiography (MRA) After a Single Intravenous Injection of 0.1 mmol/kg Gadobutrol in Subjects With Known or Suspected Vascular Disease of the Supra-aortic Vessels
Secondary ID [1] 0 0
2010-023001-36
Secondary ID [2] 0 0
14607
Universal Trial Number (UTN)
Trial acronym
GEMSAV
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carotid Stenosis 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Gadobutrol (Gadovist, BAY86-4875)

Experimental: Arm 1 -


Treatment: Drugs: Gadobutrol (Gadovist, BAY86-4875)
A single bolus injection of approx. 0.1mmol/kg
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Timepoint [1] 0 0
Images were taken pre-injection and post-injection
Primary outcome [2] 0 0
Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Timepoint [2] 0 0
Images were taken pre-injection and post-injection
Primary outcome [3] 0 0
Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Timepoint [3] 0 0
Images were taken pre-injection and post-injection
Primary outcome [4] 0 0
Minimum Gadobutrol Performance for Sensitivity: Sensitivity > 50%
Timepoint [4] 0 0
Images were taken pre-injection and post-injection
Primary outcome [5] 0 0
Minimum Gadobutrol Performance for Specificity: Specificity > 50%
Timepoint [5] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [1] 0 0
Vessel Diameter (Millimeter [mm]) at the Normal Point and the Narrowest Point in Gadobutrol-Enhanced MRA, Unenhanced MRA and CTA Images
Timepoint [1] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [2] 0 0
The Percentage of Segments With Artifacts Presence
Timepoint [2] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [3] 0 0
Types of Artifacts on a Segment Basis by Blinded Reader 1
Timepoint [3] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [4] 0 0
Types of Artifacts on a Segment Basis by Blinded Reader 2
Timepoint [4] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [5] 0 0
Types of Artifacts on a Segment Basis by Blinded Reader 3
Timepoint [5] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [6] 0 0
The Percentage of Location of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA
Timepoint [6] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [7] 0 0
Length of Stenosis (>=70%) in the Proximal Segments Assessed by Gadobutrol-Enhanced MRA and Unenhanced MRA
Timepoint [7] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [8] 0 0
The Percentage of Presence of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease
Timepoint [8] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [9] 0 0
Type of Secondary Radiologic Indicators for Diagnosis of Clinically Relevant Disease
Timepoint [9] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [10] 0 0
Diagnostic Confidence by the Blinded Readers Using Gadobutrol-Enhanced MRA and Unenhanced MRA
Timepoint [10] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [11] 0 0
The Percentage of Participants With Additional Imaging Studies Recommended by the Blinded Readers and the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images
Timepoint [11] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [12] 0 0
Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 1
Timepoint [12] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [13] 0 0
Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 2
Timepoint [13] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [14] 0 0
Types of Additional Imaging Studies Recommended by the Blinded Readers After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images - Blinded Reader 3
Timepoint [14] 0 0
Images were taken pre-injection and post-injection
Secondary outcome [15] 0 0
Types of Additional Imaging Studies Recommended by the Clinical Investigator After Evaluation of the Unenhanced and Gadobutrol-Enhanced MRA Images
Timepoint [15] 0 0
Images were taken pre-injection and post-injection

Eligibility
Key inclusion criteria
* Male or female subjects, aged 18 years and older
* Any of the following:

* Known or suspected supra-aortic arterial disease based on:

* Prior stroke
* Transient ischemic attack (TIA)
* Amaurosis Fugax (transient monocular blindness)
* Referred for evaluation of any supra-aortic vessel (for clinically significant stenosis)
* Follow-up for a stent in a supra-aortic vessel
* Prior imaging study (CTA or ultrasound) showing = 50% stenosis of a supra-aortic vessel segment (within 60 days before consent). The proportion of subjects with positive disease (determined by the investigator, based on CTA or ultrasound) will be monitored during the study, and enrolment may be further restricted to require = 70% stenosis to ensure that overall there are an adequate number of subjects with clinically significant disease for the evaluation of study endpoints.
* Willingness to undergo the routine Contrast Enhanced Magnetic Resonance Angiography [CE MRA] examination with gadobutrol
* Willingness and ability to follow directions and complete all study procedures specified in the protocol
* Females of childbearing potential only: Negative pregnancy test on the day of the MRA before the administration of study drug
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnant or nursing (including pumping for storage and feeding)
* Received any other investigational product or participation in any other clinical trial within 30 days before enrollment into this study
* Previous enrollment into this study or into any other Bayer sponsored study using gadobutrol
* Contraindication to the MRA examinations (e.g. inability to hold breath; severe arrhythmias; very low cardiac output, severe claustrophobia, defibrillators or other metallic devices not approved for MRI)
* Contraindication to the use of Gd-containing contrast agents (including subjects with suspicion for or known to have Nephrogenic Systemic Fibrosis [NSF])
* History of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents
* Received any contrast agent within 72 hours before the study MRA, or scheduled receipt of any contrast agent within 24 hours after the study MRA (Note: This applies also to a CTA potentially scheduled during the course of the study.)
* Estimated glomerular filtration rate (eGFR) value < 30 ml/min/1.73 m2 derived from a serum creatinine result within 2 weeks before the gadobutrol injection. Any subject on hemodialysis or peritoneal dialysis is excluded from participation. Use the value obtained prior to and closest to the time of the MRA, if there are multiple creatinine values. (Do not use the core lab value if not available prior to the MRA.)
* Acute renal insufficiency of any intensity, either due to hepato-renal syndrome or occurring in the peri-operative liver transplantation period
* Severe cardiovascular disease (e.g. acute myocardial infarction [< 14 days], unstable angina, congestive heart failure New York Heart Association class IV) or known long QT syndrome
* Suspected clinical instability or unpredictability of the clinical course during the study period (e.g. due to previous surgery)
* Scheduled or potentially expected for the period between the CTA and gadobutrol MRA:

* Any procedure that may alter the MRA or CTA interpretation, or
* Any interventional or surgical procedure involving the supra-aortic vessels

Study design
Purpose of the study
Diagnosis
Allocation to intervention
NA
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/05/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
28/05/2014
Sample size
Target
Accrual to date
Final
479
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
- New Lambton Heights
Recruitment hospital [2] 0 0
- Clayton
Recruitment hospital [3] 0 0
- Parkville
Recruitment postcode(s) [1] 0 0
2305 - New Lambton Heights
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Mississippi
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
Rhode Island
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Ciudad Auton. De Buenos Aires
Country [17] 0 0
Austria
State/province [17] 0 0
Tirol
Country [18] 0 0
Austria
State/province [18] 0 0
Wien
Country [19] 0 0
China
State/province [19] 0 0
Shanghai
Country [20] 0 0
Czechia
State/province [20] 0 0
Brno
Country [21] 0 0
France
State/province [21] 0 0
Brest Cedex
Country [22] 0 0
France
State/province [22] 0 0
BRON Cedex
Country [23] 0 0
France
State/province [23] 0 0
Marseille
Country [24] 0 0
France
State/province [24] 0 0
Paris Cedex 15
Country [25] 0 0
France
State/province [25] 0 0
Paris
Country [26] 0 0
Germany
State/province [26] 0 0
Baden-Württemberg
Country [27] 0 0
Germany
State/province [27] 0 0
Bayern
Country [28] 0 0
Germany
State/province [28] 0 0
Nordrhein-Westfalen
Country [29] 0 0
Germany
State/province [29] 0 0
Thüringen
Country [30] 0 0
Italy
State/province [30] 0 0
Emilia-Romagna
Country [31] 0 0
Italy
State/province [31] 0 0
Lazio
Country [32] 0 0
Italy
State/province [32] 0 0
Sicilia
Country [33] 0 0
Italy
State/province [33] 0 0
Toscana
Country [34] 0 0
Italy
State/province [34] 0 0
Valle d'Aosta
Country [35] 0 0
Italy
State/province [35] 0 0
Veneto
Country [36] 0 0
Korea, Republic of
State/province [36] 0 0
Gwangju Gwang''yeogsi
Country [37] 0 0
Korea, Republic of
State/province [37] 0 0
Seoul
Country [38] 0 0
Poland
State/province [38] 0 0
Bydgoszcz
Country [39] 0 0
Poland
State/province [39] 0 0
Lodz
Country [40] 0 0
Poland
State/province [40] 0 0
Warszawa
Country [41] 0 0
Poland
State/province [41] 0 0
Wroclaw
Country [42] 0 0
Sweden
State/province [42] 0 0
Linköping
Country [43] 0 0
Sweden
State/province [43] 0 0
Uppsala
Country [44] 0 0
Switzerland
State/province [44] 0 0
Sankt Gallen
Country [45] 0 0
Turkey
State/province [45] 0 0
Antalya
Country [46] 0 0
Turkey
State/province [46] 0 0
Erzurum
Country [47] 0 0
Turkey
State/province [47] 0 0
Istanbul

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01344447